Leukemia relapse drug combo study stopped early after enrolling just one person
NCT ID NCT05799079
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 18 times
Summary
This study tested a combination of two drugs (DEC-C and venetoclax) for people whose acute myeloid leukemia (AML) returned after a donor stem cell transplant. The goal was to see if the drugs could kill cancer cells and bring about remission. However, the study was stopped early and only enrolled one participant, so we have very limited information about how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.